Drugs / Treprostinil Palmitil
Treprostinil Palmitil
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07643155 | Jun 2026 → Feb 2027 expected | — | Insmed Incorporated | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06091579 | Sep 2020 → Jan 2021 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05176951 | Dec 2022 → Mar 2024 | pulmonary hypertension | Insmed Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT05147805 | Aug 2022 → Mar 2025 | pulmonary arterial hypertension | Insmed Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT04791514 | Mar → Aug 2022 | pulmonary arterial hypertension | Insmed Incorporated | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05649722 | May 2023 → Apr 2026 | interstitial lung disease, pulmonary hypertension | Insmed Incorporated | Completed | No outcome recorded |
| Phase 2/3 | NCT05649748 | Mar 2023 → Dec 2026 expected | pulmonary arterial hypertension | Insmed Incorporated | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07481981 | Jun 2026 → Dec 2028 expected | pulmonary arterial hypertension | Insmed Incorporated | Recruiting | No outcome recorded |
| Phase 3 | NCT07234032 | Jun 2026 → Jan 2031 expected | interstitial lung disease, pulmonary hypertension | Insmed Incorporated | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07179380 | Jan 2026 → Dec 2028 expected | interstitial lung disease, pulmonary hypertension | Insmed Incorporated | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06939647 | — | pulmonary arterial hypertension, pulmonary hypertension owing to lung disease and/or hypoxia | Insmed Incorporated | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-07-16 | Insmed Incorporated | Results Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension insmed.com ↗
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). |
| 2026-02-19 | Insmed Incorporated | Regulatory Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update insmed.com ↗
FDA grants Orphan Drug Designation to Treprostinil Palmitil for Treatment of PAH |
| 2025-06-10 | Insmed Incorporated | Results Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension insmed.com ↗
The study met its primary endpoint and all secondary efficacy endpoints. |
| 2025-05-21 | Insmed Incorporated | Results Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study insmed.com ↗
These showcased new findings from an expanded Phase 2 analysis for treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) |
| 2024-05-09 | Insmed Incorporated | Results Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update insmed.com ↗
Today, Insmed reported topline safety and tolerability data as well as certain exploratory efficacy endpoints from the Phase 2 study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). |
| 2023-05-22 | Insmed Incorporated | Results Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference insmed.com ↗
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2023 International Conference in Washington, D.C. |
| 2022-05-17 | Insmed Incorporated | Results Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference insmed.com ↗
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2022 International Conference. |
| 2021-02-19 | Insmed Incorporated | Results Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) insmed.com ↗
Data from the study demonstrated that TPIP was generally safe and well tolerated, with a pharmacokinetic profile that supports once-daily dosing. |
All press releases naming this drug 10 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treprostinil Palmitil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05147805 ↗ |
| Known as | Hexadecyl treprostinil | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650232 ↗ |
| Known as | INS-1009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650232 ↗ |
| Known as | TPIP | “Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease” NCT06939647 ↗6“An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)” NCT05649748 ↗ “Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of” PMID 36070132 ↗ Sep 2022 “Treprostinil Palmitil Inhalation Powder (TPIP)” NCT07481981 ↗ “Treprostinil Palmitil Inhalation Powder (TPIP)” NCT05649722 ↗ “Treprostinil Palmitil Inhalation Powder (TPIP)” NCT07179380 ↗ “Treprostinil Palmitil Inhalation Powder (TPIP)” NCT07234032 ↗ |
| Known as | Treprostinil hexadecyl ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650232 ↗ |
| Modality | Small molecule | — CHEMBL4650232 ↗ |
| Route | Inhaled | “via oral inhalation” NCT04791514 ↗ |